Fig. 2From: Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitisPET-CT images of patients treated with axicabtagene ciloleucel. Pre-CAR-T (above) ad post-CAR-T (below) images show improvement in left cervical and left paraaortic lymphadenopathy in patient 10 and improvement in left cervical lymphadenopathy in patient 7Back to article page